Staphylococcus aureus enterotoxin C2 mutants: biological activity assay in vitro

Area of Science:

• Immunology
• Microbiology
• Biochemistry

Background:

• Staphylococcal enterotoxin C2 (SEC2) is a bacterial superantigen from Staphylococcus aureus.
• SEC2 activates T cells, leading to cytokine release and significant anti-tumor effects in vitro and in vivo.
• The emetic (vomiting-inducing) activity of SEC2 limits its clinical application for cancer treatment.

Purpose of the Study:

• To inactivate the emetic activity of SEC2 using site-directed mutagenesis.
• To assess the impact of mutations on SEC2's T cell stimulation and anti-tumor efficacy.

Main Methods:

• Site-directed mutagenesis was employed to alter specific amino acid residues (Cys93, Cys110, His118) in SEC2.
• Mutated SEC2 proteins were tested for their ability to stimulate peripheral blood mononuclear cells (PBMCs).
• In vitro anti-tumor activity of the mutated proteins was evaluated.

Main Results:

• Mutated SEC2 proteins retained the capacity to stimulate T cells effectively.
• The modified SEC2 variants demonstrated comparable tumor-inhibition effects to the wild-type SEC2.
• The specific mutations successfully inactivated the emetic properties of SEC2.

Conclusions:

• Site-directed mutagenesis can successfully eliminate the emetic activity of SEC2.
• Mutated SEC2 retains its beneficial T cell activation and anti-tumor properties.
• This approach may yield safer and more applicable agents for clinical cancer therapy.